UBX News and Press, Unity Biotechnology Inc. From 04/17/23

2023-04-17 13:18:04 ET Gainers: Presto Automation ( PRST ) +183% . Windtree Therapeutics ( WINT ) +175% . Blackboxstocks ( BLBX ) +125% . Prometheus Biosciences ( RXDX ) +69% . Peakstone Realty Trust ( PKST ) +46% . Dragonfly...

2023-04-11 16:25:47 ET Unity Biotechnology ( NASDAQ: UBX ) said its chief medical officer Jamie Dananberg would leave the company, effective April 30. The company said Dananberg  would receive a severance payment equal to nine months of his base salary and continued ...

2023-03-27 13:06:40 ET Gainers: WiSA Technologies ( WISA ) +93% . First Citizens BancShares ( FCNCA ) +50% . Alimera Sciences ( ALIM ) +38% . Cimpress ( CMPR ) +30% . Gorilla Technology Group ( GRRR ) +25% . CBL International...

2023-03-27 08:52:49 ET Unity Biotechnology UBX -47% after mid-stage setback for wet AMD candidate . NuCana ( NCNA ) -28% after the European Patent Office issues oral ruling that NuCana's '190 patent is not valid . Pharming Group PHAR -13% erasing today'...

2023-03-27 08:32:38 ET Unity Biotechnology ( NASDAQ: UBX ) lost ~48% pre-market Monday after announcing that its lead candidate UBX1325 failed to outperform Regeneron’s ( REGN ) blockbuster eye therapy aflibercept in a Phase 2 trial for wet age-related macular deg...

UBX1325 monotherapy did not achieve non-inferiority through 24 weeks due, in part, to an unexpected 3.5 letter gain in the anti-VEGF control arm UBX1325 maintained visual acuity in patients with ongoing active disease through 24 weeks with less than one letter mean decrease from baseline ...

2023-03-15 16:49:11 ET Unity Biotechnology press release ( NASDAQ: UBX ): Q4 Non-GAAP EPS of -$1.00. Cash, cash equivalents and marketable securities totaled $94.8 million as of December 31, 2022 compared with $90.1 million as of December 31, 2021. Operating loss for t...

SOUTH SAN FRANCISCO, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the fourth quarter and full year ended December 31, 202...

2023-03-05 07:14:56 ET Summary Shares of ophthalmology concern Unity Biotechnology are down some 90% since our last look in March 2021 as a news vacuum following a failed Phase 2 trial in October. That said, the company was able to leverage good interim data from its only clinical...

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the Company’s Management will provide a corporat...